MF assessment and treatment an ‘evolution’ from the past

Print Friendly, PDF & Email


mesa-ruben-ASCO15_Zach_Boyden-Holmes_230.jpg
Ruben Mesa, MD
© ASCO/Zach Boyden-Holmes

The 11th NCCN Congress: Hematologic Malignancies coincided with the release of the inaugural edition of the NCCN treatment guideline on myeloproliferative neoplasms (MPNs), and Ruben A. Mesa, MD, took the opportunity to discuss the framework of the document and the evolving management of MPNs. Dr Mesa, of the Mayo... [Read Article]

Print Friendly, PDF & Email

Supportive care isn’t palliative care, speaker says

Print Friendly, PDF & Email


nurse_explaining_info_in_pamphlet_NCI_230.jpg
Nurse converses with patient
Photo courtesy of NCI

Two presentations at the NCCN 11th Annual Congress: Hematologic Malignancies addressed the importance of supportive care in the treatment of patients with T-cell lymphomas and multiple myeloma. Erin Kopp, ACNP-BC, of City of Hope Comprehensive Cancer Center in Duarte, California, reminded the audience that supportive care... [Read Article]

Print Friendly, PDF & Email

Speaker outlines importance of cell of origin in DLBCL

Print Friendly, PDF & Email


Zelenetz_NCCN2016.jpg
Andrew Zelenetz, MD, PhD

The importance of cell of origin in choosing a treatment for diffuse large B-cell lymphoma (DLBCL) is a topic “that has been kicking around for 16 years,” according to a speaker at the NCCN 11th Annual Congress: Hematologic Malignancies. Cell of origin was first described in the year 2000 as a... [Read Article]

Print Friendly, PDF & Email

‘Practice-changing’ treatments emerging in AML

Print Friendly, PDF & Email


AML_in_bone_marrow_240.jpg
AML cells in bone marrow

We are “finally” making progress in the treatment of acute myeloid leukemia (AML), according to a speaker at the NCCN 11th Annual Congress: Hematologic Malignancies. Jessica K. Altman, MD, said a number of developments have resulted in improved AML treatment, including a better understanding of biology and prognostic assessment, continued... [Read Article]

Print Friendly, PDF & Email

Doc offers advice on choosing a frontline TKI

Print Friendly, PDF & Email


imatinib_tablet_Credit_D_Meyer_230.jpg
Imatinib (Gleevec) tablet
Photo by D. Meyer

Evaluating treatment goals is essential when choosing which tyrosine kinase inhibitor (TKI) to prescribe a patient with newly diagnosed chronic myeloid leukemia (CML), according to a speaker at the NCCN 11th Annual Congress: Hematologic Malignancies. “Deciding what TKI to start people on really depends on what your... [Read Article]

Print Friendly, PDF & Email